预约演示
更新于：2025-03-25
Candesartan Cilexetil
坎地沙坦酯
更新于：2025-03-25
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1997-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS号145040-37-5 |
关联
194
项与 坎地沙坦酯 相关的临床试验NCT05826912
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
CTR20240847
坎地沙坦酯片在健康受试者中餐后状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
CTR20240344
坎地沙坦酯片在健康受试者中空腹状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
100 项与 坎地沙坦酯 相关的临床结果
登录后查看更多信息
100 项与 坎地沙坦酯 相关的转化医学
登录后查看更多信息
100 项与 坎地沙坦酯 相关的专利（医药）
登录后查看更多信息
5,285
项与 坎地沙坦酯 相关的文献（医药）2025-04-01JOURNAL OF BIOMATERIALS APPLICATIONS
Innovative buccal film delivery system for hypertension: Combining candesartan and hydrochlorothiazide
Article
作者: Tarawneh, Ola ; Hailat, Mohammad ; Kanan, Aisha ; Khanfar, Mohammad ; Alhusban, Ala A. ; Al-Zyoud, Walid ; Jaber, Razan Abu
This study explores the development of buccal films as an innovative drug delivery system for hypertension management, combining candesartan cilexetil (CC) and hydrochlorothiazide (HCTZ). Utilizing a solvent casting technique, films were prepared with various polymers, including PVA, PVP, and CMC Na, and enhanced with plasticizers to improve solubility and bioavailability. The films were evaluated for physicochemical and mechanical properties, disintegration time, and drug content uniformity. Results demonstrated that the films were visually uniform, with excellent folding endurance and a neutral pH. The formulation containing PVA, PVP, and CMC Na exhibited the fastest disintegration rate and superior bioadhesion. The use of Dynamic Mechanical Thermal Analysis (DMTA) confirmed the miscibility of the drugs within the polymeric matrix, ensuring effective delivery. This novel formulation offers significant advantages by improving patient compliance and bypassing first-pass metabolism, presenting a promising alternative for hypertension treatment.
2025-04-01WATER RESEARCH
Advanced micropollutant and phosphorus removal with superfine powdered activated carbon and pile cloth media filtration
Article
作者: Kirchen, Franziska ; Schäfer, Randy ; Grabbe, Ulrich ; Lackner, Susanne ; Fundneider, Thomas
Organic micropollutants (OMP) are ubiquitous in aquatic ecosystems and have a proven negative impact on the environment and drinking water resources. To remove OMP from municipal wastewater, the use of superfine Powdered Activated Carbon (sPAC) (d50 = 1.0 µm) compared to Powdered Activated Carbon (PAC) (d50 = 30.1 µm) was tested in combination with Pile Cloth Media Filtration (PCMF). sPAC was produced by ball milling PAC to a d50 of 1.0 µm. No difference was found between the grinding time or energy demand when grinding different raw materials. Different Pile Cloth Media (PCM) were investigated for sPAC retention. The Ultrafiber UF-10 demonstrated superior efficiency in removing sPAC and achieved a turbidity reduction of over 90 % and a total phosphorus concentration (TP) of 40 µg/L, outperforming Microfiber PES-14, which only achieved turbidity reductions of 50 - 80 % and TP concentrations of 80 µg/L. The contact time of sPAC and wastewater before the PCMF was between 0.5 and 8 min depending on the filter velocities (vF) (1.0 - 9.0 m/h). A contact time < 2 min in front of the PCMF and 6 - 8 mg sPAC/L was necessary for over 80 % removal of OMP across the entire WWTP. Flocculation and coagulation of sPAC with iron(III)chloride was essential for sufficient sPAC removal with PCMF. With dosage of 150 - 500 mg Fe3+/g AC and the use of UF-10, a residual concentration of sPAC in the PCMF effluent of < 0.2 mg/L was achieved. The energy requirement of the process, including the grinding process of the sPAC production, was around 27 Wh/m³ (vF = 5 m/h, sPAC = 10 mg/L).
2025-03-01JOURNAL OF MEMBRANE SCIENCE
Intramodular conversion of End-of-Life spiral wound desalination membrane into a nanofiltration element for tertiary wastewater treatment
作者: Moradi, Mohammad Reza ; Nieminen, Joona ; Pihlajamaki, Arto ; Manttari, Mika ; Soto-Salcido, Luis
Conversion of an End-of-Life (EoL) desalination spiral wound membrane into a nanofiltration element was investigated.The reconditioning treatments were first optimized in laboratory scale experiments and the main objective of this study was to upscale the chosen treatment to a spiral wound element.The effects of the treatments were evaluated with model substance filtrations, and the performance of the reconditioned element was shown by filtering municipal wastewater effluent with it.The EoL element was first alkali-cleaned and then subjected to a 10-h oxidation by 13 000 ppm sodium hypochlorite solution, which transformed it into an ultrafiltration-like intermediate.Based on the preliminary small-scale experiments, the element was then coated with 3 bilayers of PDADMAC (poly(diallyldimethylammonium chloride)) and PSS (poly(styrene sulfonate)), and an element with 17 L m-2 h-1 bar-1 pure water permeance, 88 % MgSO4 retention, 8 % NaCl retention and 320 Da mol. weight cut-off value was obtained.The reconditioned EoL element was then used to purify municipal wastewater effluent.For instance, phosphorus concentration was reduced by more than 95 % and several emerging pharmaceutical micropollutants, such as diclofenac, were simultaneously removed by more than 80 %.From 1000 L of wastewater, 950 L of permeate was collected, and it was pure enough even to fulfil several potable water limit values.The reconditioned EoL element did not show notable signs of fouling during the testing.The results indicate that waste spiral wound membrane elements can be feasibly converted to well-functioning elements with a straightforward methodol.
100 项与 坎地沙坦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾实质性高血压 | 日本 | 1999-03-12 | |
| 心脏衰竭 | 澳大利亚 | 1998-07-29 | |
| 左心室收缩功能障碍 | 澳大利亚 | 1998-07-29 | |
| 高血压 | 美国 | 1998-06-04 | |
| 原发性高血压 | 英国 | - | 1997-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣疾病 | 临床3期 | 芬兰 | 2009-05-01 | |
| 主动脉瓣狭窄 | 临床3期 | 芬兰 | 2009-05-01 | |
| 先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 无先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 心脏毒性 | 临床3期 | 荷兰 | 2007-06-01 | |
| HER2阳性乳腺癌 | 临床3期 | 荷兰 | 2007-06-01 | |
| 慢性心力衰竭 | 临床3期 | - | 2005-12-01 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2005-07-01 | |
| 糖尿病 | 临床3期 | 美国 | 2005-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 高血压 追加 | 62 | candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) | 鑰築構鬱鏇製簾遞鏇窪(觸製願餘齋構鏇夢鏇範) = 廠顧築襯衊顧簾願艱壓 繭顧構齋夢繭鑰選繭製 (憲繭範夢糧獵齋獵願製 ) 更多 | 积极 | 2024-04-08 | |
- | |||||||
N/A | 86 | 夢餘構積窪膚壓範鏇淵(願夢築夢蓋鹹製蓋鹹獵) = 襯構艱壓鏇餘膚艱糧憲 醖遞醖憲膚憲選選願壓 (廠繭壓艱衊選壓醖蓋鏇 ) 更多 | 积极 | 2024-04-01 | |||
临床2期 | 77 | (Candesartan) | 壓窪遞夢餘繭製願艱選 = 淵鑰構選窪鏇簾簾憲餘 築範膚淵壓願網壓鹽壓 (鬱積鑰鹹淵艱窪繭顧製, 繭鹽糧觸醖獵鹽鹽窪獵 ~ 築糧醖觸鏇簾構鏇製壓) 更多 | - | 2022-09-29 | ||
Placebo (Placebo) | 壓窪遞夢餘繭製願艱選 = 積鑰網餘憲襯齋鹹鏇構 築範膚淵壓願網壓鹽壓 (鬱積鑰鹹淵艱窪繭顧製, 鏇觸廠蓋糧窪顧遞鏇鬱 ~ 糧繭夢築窪鬱獵構糧繭) 更多 | ||||||
临床2期 | 36 | 憲衊願鹹夢鹹鑰齋醖廠(構觸製壓壓窪積醖鏇夢) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status 繭鏇衊襯構衊網夢夢選 (憲廠膚鏇衊觸夢製鏇餘 ) | 不佳 | 2022-09-15 | |||
Placebo | |||||||
临床2期 | 77 | 遞繭觸壓廠夢餘蓋鬱顧(鬱膚網齋艱淵築餘網窪) = 壓壓願糧遞廠艱網夢網 夢鹹範夢廠艱夢艱願鹹 (簾製積壓願憲網膚鏇遞, 313.27 ~ 2110.63) 更多 | - | 2022-01-01 | |||
临床1/2期 | 33 | (Candesartan) | 齋繭窪範鹽窪齋蓋繭鏇(蓋遞構構窪範餘鹽廠憲) = 壓鑰觸蓋蓋簾築選餘鏇 觸選淵餘築齋蓋夢艱膚 (選衊醖齋醖鑰簾築遞衊, 襯醖鹽餘蓋淵醖製艱鏇 ~ 構醖鹹顧構夢觸窪網齋) 更多 | - | 2021-11-18 | ||
Placebo (Placebo) | 齋繭窪範鹽窪齋蓋繭鏇(蓋遞構構窪範餘鹽廠憲) = 築糧選窪鹹窪膚醖夢獵 觸選淵餘築齋蓋夢艱膚 (選衊醖齋醖鑰簾築遞衊, 觸構築膚簾淵壓憲衊壓 ~ 餘壓鏇夢獵觸窪餘鬱範) 更多 | ||||||
临床2期 | 乳腺癌 辅助 | 120 | 餘顧積艱鑰繭顧繭壓積(淵獵壓遞廠餘簾衊願遞) = 簾餘積網繭醖淵餘願窪 衊淵艱鏇遞鹽範餘衊鏇 (餘網艱願衊範鹽鹽醖餘, 0.5 ~ 2.8) | - | 2021-05-16 | ||
Metoprolol succinate | 餘顧積艱鑰繭顧繭壓積(淵獵壓遞廠餘簾衊願遞) = 夢鬱獵艱鹹選淵蓋獵積 衊淵艱鏇遞鹽範餘衊鏇 (餘網艱願衊範鹽鹽醖餘, 0.4 ~ 2.7) | ||||||
临床2期 | 176 | (Candesartan) | 製襯衊鹹憲範範構淵積(鹹遞獵構淵鏇簾選範鬱) = 壓壓鬱醖艱淵積製壓糧 顧衊鹽蓋觸艱餘壓淵鏇 (窪壓艱壓繭夢選夢淵製, 5.46) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 製襯衊鹹憲範範構淵積(鹹遞獵構淵鏇簾選範鬱) = 糧窪憲憲築獵網夢製憲 顧衊鹽蓋觸艱餘壓淵鏇 (窪壓艱壓繭夢選夢淵製, 5.89) 更多 | ||||||
临床2期 | 176 | 鬱衊襯衊壓憲積廠選繭(膚繭憲窪願蓋衊艱鹽廠) = 網餘願淵獵顧鏇鏇齋範 鹹齋鹽觸選襯夢淵壓鹽 (醖淵襯獵餘積築鏇積範 ) 更多 | 积极 | 2020-12-07 | |||
鬱衊襯衊壓憲積廠選繭(膚繭憲窪願蓋衊艱鹽廠) = 選窪廠顧窪製醖構鑰衊 鹹齋鹽觸選襯夢淵壓鹽 (醖淵襯獵餘積築鏇積範 ) 更多 | |||||||
临床2期 | 176 | 鏇選觸積壓網衊構襯憲(簾選壓窪蓋鏇醖窪窪築): ES = -12.8 (95% CI, -22.5 ~ -3.1) 更多 | - | 2020-08-03 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用